What Is MSI-H in Colorectal Cancer?
On this page
Microsatellite instability-high (MSI-H) refers to colorectal tumors that have a significant amount of instability in short, repeated DNA sequences called microsatellites. These regions are scattered across the genome and are prone to errors during cell division. When the DNA repair system is faulty, these errors accumulate, leading to MSI-H status. People often ask about MSI-H to understand how this biomarker affects diagnosis, prognosis, and treatment.
What Causes MSI-H in Colorectal Cancer?
MSI-H occurs when the mismatch repair (MMR) system—which fixes DNA copying mistakes—fails to function properly. This can happen:
- Sporadically:From changes acquired in the tumor, often involving epigenetic silencing of genes like MLH1.
- Inherited:As part of Lynch syndrome, where mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) are passed down and increase cancer risk.
In many MSI-H cases, at least one MMR protein is missing or nonfunctional, but not all MSI-H tumors are linked to Lynch syndrome; many are sporadic.
MSI-H vs MSS in Colorectal Cancer
Colorectal tumors are classified as:
- MSI-H: Instability at several microsatellite markers.
- MSI-L: Instability at only one marker.
- MSS (microsatellite stable): No instability detected.
The main distinction is the extent of microsatellite instability and the function of the MMR system. MSI-H tumors often behave differently, have unique prognosis patterns, and respond differently to treatments—especially immunotherapy—compared to MSS tumors. MSI status is now a standard part of diagnosis and treatment planning.
How Is MSI Testing Performed?
- MSI Testing:Uses PCR to compare microsatellite regions in tumor vs normal tissue.
- MMR Protein Testing:Uses immunohistochemistry (IHC) to check for the presence or absence of MMR proteins in tumor tissue.
- Molecular Testing:Can also be done with next-generation sequencing (NGS) panels, which may evaluate MSI status alongside other mutations. Choice of method depends on clinical context and available resources.
What Do MSI-H Test Results Mean?
- MSI-H:Indicates high microsatellite instability, usually due to MMR deficiency. This result can guide treatment decisions—especially regarding immunotherapy—and may prompt further evaluation for Lynch syndrome.
- MSS:No significant instability detected, indicating normal MMR function in the sample. MSS tumors usually do not respond as well to immunotherapy as MSI-H tumors.
- dMMR and MSI-H:These terms are related and often found together, but measure different things (protein loss vs DNA instability). Complete interpretation should be done by the oncology team.
MSI-H and Colorectal Cancer Treatment
MSI-H, Lynch Syndrome, and Genetics
Some MSI-H tumors are linked to Lynch syndrome, an inherited condition involving MMR gene mutations. Only about 3–5% of colorectal cancers are MSI-H due to Lynch syndrome; the rest are usually sporadic. Tumor biomarker tests are not the same as inherited genetic tests. If Lynch syndrome is suspected, further genetic counseling and germline testing may be needed.
MSI-H Prognosis
Prognosis depends on many factors, including cancer stage and tumor characteristics. Early-stage MSI-H colorectal cancers may have a better outlook than MSS tumors at the same stage, but MSI status should not be the sole factor in predicting outcomes—other clinical details must be considered.
Key Points MSI-H means high microsatellite instability, usually from defective mismatch repair. Causes can be sporadic or inherited (Lynch syndrome). MSI-H vs MSS status guides prognosis and therapy, especially immunotherapy. Testing uses PCR, IHC, and/or NGS approaches. MSI/MMR status is a major biomarker for colorectal cancer management. Prognosis depends on multiple clinical factors, not MSI status alone.
FAQs on MSI-H in Colorectal Cancer
What does MSI-H mean?
High microsatellite instability, often due to mismatch repair deficiency, which may affect treatment options.
Is MSI-H the same as dMMR?
They are closely related but measured differently—MSI-H looks at DNA instability, dMMR at protein loss.
How is MSI-H tested?
Through PCR-based assays, IHC for MMR proteins, or NGS panels.
Difference between MSI-H and MSS?
MSI-H tumors show high instability and often have dMMR; MSS tumors are stable and usually have normal MMR.
Does MSI-H affect treatment?
Yes, it can identify patients more likely to benefit from immune checkpoint inhibitor therapy.